2013 Biotech Boom a Bust for Women
While women earn more than half the bachelor degrees and PhDs in the biological sciences, they remain poorly represented in the leadership of start-ups. Based on analysis performed by AWIS, we find that while 2013 was a banner year for biotech initial public offerings (IPOs), it was a bust for women.
- Only one company had a female CEO
- Many companies had no women in the C suite or on their board of directors.
**Not all firms disclose lists of science/clinical advisory boards
**There are several women CEOs in biotech companies, but none of these companies are IPOs.
(data accurate as of 3.27.14)
Forbes.com "A Quick Glance At The Biotech IPO Boom" by Matthew Herper, Forbes Staff. 8/13/13.
Nasdaq.com IPO Listing
Fierce Biotech.com IPO Frenzy